SOUTH SAN FRANCISCO, Calif., June 17, 2026
Genentech, a member of the Roche Group, has reached a significant regulatory milestone after the U.S. Food and Drug Administration (FDA) accepted its supplemental Biologics License Application (sBLA) for Lunsumio VELO™ (mosunetuzumab-axgb) in combination with Polivy® (polatuzumab vedotin-piiq) for the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) following at least one prior line of systemic therapy. The acceptance marks an important step toward expanding treatment options for patients facing one of the most challenging forms of blood cancer. The regulatory filing is supported by compelling Phase III SUNMO study results demonstrating that the combination significantly reduced the risk of disease progression or death while providing a chemotherapy-free, outpatient-ready treatment approach that could improve access to care for patients treated in community settings. The FDA is expected to make its approval decision by February 9, 2027, potentially paving the way for a new standard of care in relapsed or refractory LBCL.
Phase III SUNMO Study Delivers Strong Clinical Results
The FDA acceptance is based on data from the pivotal Phase III SUNMO trial, which evaluated the efficacy and safety of the Lunsumio VELO and Polivy combination compared with the current standard regimen of rituximab, gemcitabine, and oxaliplatin (R-GemOx). Results showed a remarkable 59% reduction in the risk of disease progression or death, with patients receiving the investigational combination achieving a median progression-free survival of 11.5 months, compared with 3.8 months for those receiving standard therapy. Updated findings presented at major international oncology meetings continued to demonstrate durable clinical benefit with extended follow-up and no new safety concerns.
The combination’s safety profile remained consistent with the known characteristics of the individual therapies, while rates of cytokine release syndrome remained low and manageable. These findings reinforce the potential of the regimen to address a significant unmet need among patients whose disease has relapsed or become resistant to prior treatments.
Expanding Access Through Outpatient Cancer Care
Advertisement
Large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), remains the most common form of non-Hodgkin lymphoma, with more than 18,000 new diagnoses annually in the United States. Although many patients initially respond to frontline treatment, a substantial proportion experience relapse or refractory disease, where therapeutic options become limited and outcomes remain poor. One of the most significant advantages of the proposed Lunsumio VELO and Polivy regimen is its ability to be administered in an outpatient setting, reducing the logistical burdens often associated with advanced lymphoma treatments.
Healthcare experts note that many innovative therapies require treatment at specialized academic centers, creating barriers for patients living in rural or underserved communities. By offering a chemotherapy-free regimen suitable for community oncology practices, Genentech aims to improve treatment accessibility while ensuring patients can receive advanced care closer to home.
Strengthening Innovation in Hematologic Oncology
The regulatory milestone further strengthens Genentech’s leadership in hematology-oncology innovation and highlights the growing importance of bispecific antibodies and antibody-drug conjugates (ADCs) in cancer treatment. Lunsumio VELO is a subcutaneous CD20xCD3 T-cell-engaging bispecific antibody designed to activate a patient’s immune system against malignant B cells, while Polivy is a first-in-class anti-CD79b antibody-drug conjugate that selectively delivers cytotoxic therapy to cancerous cells. Together, the combination represents a highly targeted treatment strategy designed to improve efficacy while minimizing unnecessary toxicity.
If approved, the regimen could become a valuable option for patients with relapsed or refractory LBCL, offering a convenient and effective therapeutic alternative while supporting broader efforts to improve long-term outcomes in blood cancers. The FDA’s acceptance of the filing signals growing confidence in the potential of next-generation immuno-oncology therapies to transform lymphoma care and address longstanding unmet medical needs.
Source: Genentech press release
